- Blog article -

Customer success-story: Optomed secured 1,97 M€ EU funding for Smartscope-X – affordable, accessible and automatic screening for diabetic retinopathy

12 Oct 2017

In May, the Finnish medical technology company Optomed was granted 1,97 M€ from Horizon 2020 SME Phase 2 instrument under the topic Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well. The funding will help Optomed make their product Smartscope-X the leading solution for diabetic retinopathy screening, supporting the company’s vision to provide affordable eye screenings to everyone.

Diabetic retinopathy is the most frequent cause of preventable blindness in working-aged adults, affecting people with all types of diabetes. Visual impairment and blindness caused by diabetic retinopathy can be prevented through early and effective screening. Currently, screening is costly, time-consuming and needs to be done by an ophthalmologist. Optomed’s solution will allow patients to do the screenings automatically and get the diagnosis in real-time.

Optomed’s fully automated diabetic retinopathy screening solution consists of three main components: a low-cost handheld camera, an automated screening algorithm and a cloud service for eyeground images. As a low-cost and portable solution, Smartscope-X can also provide access to screening for example in developing countries.

Spinverse supported Optomed in project preparation, including help in defining the scope, matching the call and assisting in writing the proposal. After a positive decision from the EU Commission in May 2017, Spinverse supported Optomed in the project negotiation phase.

“The cooperation with Spinverse worked well. The applicant always has the main responsibility during the application process, but the support from Spinverse and their expertise on the application process helped us achieve the desired outcome,” says Seppo Kopsala, CEO of Optomed.

The project officially began in August. Currently, Optomed is working on product development related to the integration between the camera and the software as well as choosing subcontractors for the server solution. Next steps towards the commercialization of Smartscope-X include several clinical tests and commercial pilots in target countries during 2018–2019.

What can you achieve with EU funding? See how we have helped companies create success stories and  contact us to discuss your options.

Photo credit: Optomed

- Blog -

Relevant blog posts

Client NewsSpinverse News

Espoo won the Intelligent Community of the Year 2018 award with the help of LuxTurrim5G

8 Jun 2018

City of Espoo received the 2018 Intelligent Community of the Year award given by the Intelligent Community For...

Client NewsSpinverse News

Customer success-story: MacroArray Diagnostics secured 2,5 M€ EU funding for an allergy diagnostics innovation project

24 May 2018

Allergies and asthma affect at least a quarter of the population. While often harmless, an increasing number o...

Client NewsSpinverse News

MetGen’s Matti Heikkilä & Spinverse’s Laura Koponen on Finnish national tv Huomenta Suomi: wood to replace oil

23 May 2018

MetGen's CTO, Matti Heikkilä, and Laura Koponen, Managing Director of Spinverse were on Finnish national tv, H...

Client NewsServices

Unique bioeconomy project raises 21 million in funding. ”We produce with wood what used to be made with oil”

9 May 2018

SWEETWOODS is a 43-million-euro joint pilot project that was recently granted 21 million euros in funding unde...

Client NewsSpinverse News

LuxTurrim5G helps establish Espoo in the world’s top 7 Intelligent Communities of 2018

16 Feb 2018

LuxTurrim5G, the Nokia Bell Labs driven collaborative ecosystem project coordinated by Spinverse, enab...

Client News

Digitalising forest industry with Siemens and VTT

15 Aug 2017

Does your company have a great product, service or technology that can ra...